← Back to headlines
GSK boosts oncology with $11 billion Nuvalent acquisition
GSK is strengthening its oncology division through 'Project Nashville' with an $11 billion deal to acquire Nuvalent, aiming to rebuild its presence in cancer treatment.
11 Jun, 06:04 — 11 Jun, 06:04
Sources
Showing 1 of 1 sources
